Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article

References

• Kaseb H, Annamaraju P, Babiker HM. Monoclonal gammopathy of undetermined significance. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC; 2022.
   Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005;23(7):1564–1577. doi:10.1200/JCO.2005.03.144
   PubMed Web of Science ®Google Scholar
• ASCO. Cancer.net: ASCO; 2022.
   Google Scholar
• Landgren O. Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. Hematology Am Soc Hematol Educ Program. 2010;2010:295–302. doi:10.1182/asheducation-2010.1.295
   PubMedGoogle Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. doi:10.4065/78.1.21
   PubMed Web of Science ®Google Scholar
• Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418–5422. doi:10.1182/blood-2008-12-195008
   PubMed Web of Science ®Google Scholar
• Murray D, Kumar SK, Kyle RA, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019;9(12):102. doi:10.1038/s41408-019-0263-z
   PubMedGoogle Scholar
• Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–249. doi:10.1056/NEJMoa1709974
   PubMed Web of Science ®Google Scholar
• Thorsteinsdottir S, Kristinsson SY. The consultant’s guide to smoldering multiple myeloma. Hematology Am Soc Hematol Educ Program. 2022;2022(1):551–559. doi:10.1182/hematology.2022000355
   PubMedGoogle Scholar
• Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. 2018;131(2):163–173. doi:10.1182/blood-2017-09-807560
   PubMed Web of Science ®Google Scholar
• Waldenstrom J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1960;56:211–231.
   PubMedGoogle Scholar
• Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978;64(5):814–826. doi:10.1016/0002-9343(78)90522-3
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860–1873. doi:10.1056/NEJMra041875
   PubMed Web of Science ®Google Scholar
• Pang L, Rajkumar SV, Kapoor P, et al. Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer J. 2021;11(2):26. doi:10.1038/s41408-021-00406-6
   PubMed Web of Science ®Google Scholar
• Therneau TM, Kyle RA, Melton LJ, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012;87(11):1071–1079. doi:10.1016/j.mayocp.2012.06.014
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Palumbo A, Johnsen HE, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014;99(6):984–996. doi:10.3324/haematol.2013.100552
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812–817. doi:10.1182/blood-2005-03-1038
   PubMed Web of Science ®Google Scholar
• Kaseb H, Pavan A, Babiker HM. Monoclonal Gammopathy of Undetermined Significance. Treasure Island (FL): StatPearls; 2022.
   Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–2590. doi:10.1056/NEJMoa070389
   PubMed Web of Science ®Google Scholar
• Akhlaghi T, Maclachlan K, Korde N, et al. P886: African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients. HemaSphere. 2022;6:778–779. doi:10.1097/01.HS9.0000846420.96485.de
   Google Scholar
• Ahn IE, Mailankody S, Korde N, Landgren O. Dilemmas in treating smoldering multiple myeloma. J Clin Oncol. 2015;33(1):115–123. doi:10.1200/JCO.2014.56.4351
   PubMed Web of Science ®Google Scholar
• Tessier C, Allard T, Boudreault J-S, et al. Testing Mayo clinic’s new 20/20/20 risk model in another cohort of smoldering Myeloma patients: a retrospective study. Curr Oncol. 2021;28(3):2029–2039. doi:10.3390/curroncol28030188
   PubMed Web of Science ®Google Scholar
• Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102. doi:10.1038/s41408-020-00366-3
   PubMed Web of Science ®Google Scholar
• Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–2592. doi:10.1182/blood-2007-05-088443
   PubMed Web of Science ®Google Scholar
• Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140(8):828–838. doi:10.1182/blood.2021011670
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–447. doi:10.1056/NEJMoa1300439
   PubMed Web of Science ®Google Scholar
• Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple Myeloma. J Clin Oncol. 2020;38(11):1126–1137. doi:10.1200/JCO.19.01740
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Martinez Lopez J, Rodríguez-Otero P, et al. Curative strategy (GEM-CESAR) for high-risk Smoldering Myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd. Blood. 2021;138(Supplement 1):1829. doi:10.1182/blood-2021-148423
   Google Scholar
• Kumar SK, Abdallah A-O, Badros AZ, et al. Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): a phase 2 trial of induction, consolidation and maintenance in subjects with high risk Smoldering Multiple Myeloma (SMM): initial analysis of safety Data. Blood. 2020;136(Supplement 1):35–36. doi:10.1182/blood-2020-142584
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA. 2020;70(1):7–30. doi:10.3322/caac.21590
   Web of Science ®Google Scholar
• Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple Myeloma: a review. JAMA. 2022;327(5):464–477. doi:10.1001/jama.2022.0003
   PubMed Web of Science ®Google Scholar
• Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016;91(6):575–580. doi:10.1002/ajh.24351
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Lazarus HM. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplant. 2006;38(1):7–15. doi:10.1038/sj.bmt.1705395
   PubMed Web of Science ®Google Scholar
• Dupuis MM, Tuchman SA. Non-secretory multiple myeloma: from biology to clinical management. Onco Targets Ther. 2016;9:7583–7590. doi:10.2147/OTT.S122241
   PubMed Web of Science ®Google Scholar
• Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012;120(1):20–30. doi:10.1182/blood-2012-01-379024
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021;96(2):258–269. doi:10.1002/ajh.26082
   PubMed Web of Science ®Google Scholar
• Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol. 2007;138(6):700–720. doi:10.1111/j.1365-2141.2007.06724.x
   PubMed Web of Science ®Google Scholar
• Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF. Waldenström’s macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer. 1998;82(6):1078–1081. doi:10.1002/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Br J Haematol. 2015;169(1):81–89. doi:10.1111/bjh.13264
   PubMed Web of Science ®Google Scholar
• Kyle RA, Larson DR, McPhail ED, et al. Fifty-year incidence of waldenström macroglobulinemia in Olmsted County, Minnesota, from 1961 through 2010: a population-based study with complete case capture and hematopathologic review. Mayo Clin Proc. 2018;93(6):739–746. doi:10.1016/j.mayocp.2018.02.011
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström’s macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18(1):214–226. doi:10.1200/JCO.2000.18.1.214
   PubMed Web of Science ®Google Scholar
• García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575–582. doi:10.1046/j.1365-2141.2001.03144.x
   PubMed Web of Science ®Google Scholar
• Kyle RA, Ansell SM, Kapoor P. Prognostic factors and indications for treatment of Waldenström’s Macroglobulinemia. Best Pract Res Clin Haematol. 2016;29(2):179–186. doi:10.1016/j.beha.2016.08.014
   PubMed Web of Science ®Google Scholar
• Pavy MD, Murphy PL, Virella G. Paraprotein-induced hyperviscosity. A reversible cause of stroke. Postgrad Med. 1980;68(3):109–112. doi:10.1080/00325481.1980.11715533
   PubMed Web of Science ®Google Scholar
• Mueller J, Hotson JR, Langston JW. Hyperviscosity-induced dementia. Neurology. 1983;33(1):101–103. doi:10.1212/WNL.33.1.101
   PubMed Web of Science ®Google Scholar
• Bloch KJ, Maki DG. Hyperviscosity syndromes associated with immunoglobulin abnormalities. Semin Hematol. 1973;10(2):113–124.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Marmiroli P, Baldini L, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology. 1987;37(9):1506–1514. doi:10.1212/WNL.37.9.1506
   PubMed Web of Science ®Google Scholar
• Chad DA, Harris NL. Case records of the Massachusetts general hospital. Weekly clinicopathological exercises. Case 16-1999. A 71-year-old man with progressive weakness and a gammopathy. N Engl J Med. 1999;340(21):1661–1669. doi:10.1056/NEJM199905273402108
   PubMed Web of Science ®Google Scholar
• Charakidis M, Russell DJ. Spontaneous splenic rupture in Waldenstrom’s macroglobulinemia: a case report. J Med Case Rep. 2010;4:300. doi:10.1186/1752-1947-4-300
   PubMedGoogle Scholar
• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):110–115. doi:10.1053/sonc.2003.50082
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833. doi:10.1056/NEJMoa1200710
   PubMed Web of Science ®Google Scholar
• Zanwar S, Abeykoon JP. Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond. Ther Adv Hematol. 2022;13:20406207221093962. doi:10.1177/20406207221093962
   Web of Science ®Google Scholar
• Ihne S, Morbach C, Sommer C, Geier A, Knop S, Störk S. Amyloidosis-the diagnosis and treatment of an underdiagnosed disease. Dtsch Arztebl Int. 2020;117(10):159–166. doi:10.3238/arztebl.2020.0159
   PubMed Web of Science ®Google Scholar
• ASCO. Amyloidosis: statistics; 2022.
   Google Scholar
• Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046–1053. doi:10.1182/bloodadvances.2018016402
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806. doi:10.1093/eurheartj/ehx589
   PubMed Web of Science ®Google Scholar
• Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215–219. doi:10.1080/13506129.2018.1549825
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159–168. doi:10.1182/blood-2016-01-629790
   PubMed Web of Science ®Google Scholar
• Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–1043. doi:10.1136/jnnp-2014-308724
   PubMed Web of Science ®Google Scholar
• Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289(3):268–292. doi:10.1111/joim.13169
   PubMed Web of Science ®Google Scholar
• Ash S, Shorer E, Ramgobin D, et al. Cardiac amyloidosis-A review of current literature for the practicing physician. Clin Cardiol. 2021;44(3):322–331. doi:10.1002/clc.23572
   PubMed Web of Science ®Google Scholar
• Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012;79(6):733–748. doi:10.1002/msj.21352
   PubMedGoogle Scholar
• Rowe K, Pankow J, Nehme F, Salyers W. Gastrointestinal Amyloidosis: review of the Literature. Cureus. 2017;9(5):e1228. doi:10.7759/cureus.1228
   PubMedGoogle Scholar
• Pinto V, Bergantim R, Caires HR, Seca H, Guimarães JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers. 2020;12(2):407. doi:10.3390/cancers12020407
   PubMed Web of Science ®Google Scholar
• Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple Myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228–1263. doi:10.1200/JCO.18.02096
   PubMed Web of Science ®Google Scholar
• Harousseau JL. How to select among available options for the treatment of multiple myeloma. Ann Oncol. 2012;23(Suppl 10):x334–8. doi:10.1093/annonc/mds311
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. doi:10.1038/nrdp.2017.46
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2018;93(8):981–1114. doi:10.1002/ajh.25117
   PubMed Web of Science ®Google Scholar
• Kumar SK. Recycling therapies for myeloma: the need for prospective trials. Cancer. 2019;125(17):2920–2922. doi:10.1002/cncr.32177
   PubMed Web of Science ®Google Scholar
• Poczta A, Rogalska A, Marczak A. Treatment of multiple Myeloma and the role of melphalan in the era of modern therapies-current research and clinical approaches. J Clin Med. 2021;10(9):1841. doi:10.3390/jcm10091841
   PubMed Web of Science ®Google Scholar
• Dima D, Jiang D, Singh DJ, et al. Multiple Myeloma therapy: emerging trends and challenges. Cancers. 2022;14(17):4082. doi:10.3390/cancers14174082
   PubMed Web of Science ®Google Scholar
• Mateos MV, Bladé J, Bringhen S, et al. Melflufen: a peptide-drug conjugate for the treatment of multiple myeloma. J Clin Med. 2020;9(10):3120. doi:10.3390/jcm9103120
   PubMed Web of Science ®Google Scholar
• Ito S. Proteasome inhibitors for the treatment of multiple Myeloma. Cancers. 2020;12(2):265. doi:10.3390/cancers12020265
   PubMed Web of Science ®Google Scholar
• Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947–959. doi:10.1182/blood-2012-04-403733
   PubMed Web of Science ®Google Scholar
• Herndon TM, Deisseroth A, Kaminskas E, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19(17):4559–4563. doi:10.1158/1078-0432.CCR-13-0755
   PubMed Web of Science ®Google Scholar
• Efentakis P, Kremastiotis G, Varela A, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019;133(7):710–723. doi:10.1182/blood-2018-06-858415
   PubMed Web of Science ®Google Scholar
• Tzogani K, Florez B, Markey G, et al. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open. 2019;4(5):e000570. doi:10.1136/esmoopen-2019-000570
   PubMed Web of Science ®Google Scholar
• Sharma S, Lichtenstein A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood. 2008;112(4):1338–1345. doi:10.1182/blood-2007-11-124156
   PubMed Web of Science ®Google Scholar
• Friedenberg WR, Kyle RA, Knospe WH, Bennett JM, Tsiatis AA, Oken MM. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol. 1991;36(3):171–175. doi:10.1002/ajh.2830360303
   PubMed Web of Science ®Google Scholar
• Kumar SK, Laubach JP, Giove TJ, et al. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol. 2017;178(5):756–763. doi:10.1111/bjh.14754
   PubMed Web of Science ®Google Scholar
• Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple Myeloma. Cancers. 2021;13(4):863. doi:10.3390/cancers13040863
   PubMed Web of Science ®Google Scholar
• McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2(8354):822–824. doi:10.1016/S0140-6736(83)90739-0
   PubMed Web of Science ®Google Scholar
• Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70(3):869–872. doi:10.1182/blood.V70.3.869.869
   PubMed Web of Science ®Google Scholar
• Wildes TM, Finney JD, Fiala M, et al. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Bone Marrow Transplant. 2015;50(8):1075–1082. doi:10.1038/bmt.2015.106
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905. doi:10.1056/NEJMoa1402888
   PubMed Web of Science ®Google Scholar
• Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456–e68. doi:10.1016/S2352-3026(20)30099-5
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320. doi:10.1056/NEJMoa1611750
   PubMed Web of Science ®Google Scholar
• Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–1629. doi:10.1016/S1470-2045(15)00389-7
   PubMed Web of Science ®Google Scholar
• Kumar L, Hussain MM, Chethan R, et al. Multiple Myeloma: impact of time to transplant on the outcome. Clin Lymphoma Myeloma Leuk. 2022;22(9):e826–e35. doi:10.1016/j.clml.2022.04.020
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jacobus SJ, Weller E, et al. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): the phase 3 DETERMINATION trial. J Clin Oncol. 2022;40(17_suppl):LBA4–LBA. doi:10.1200/JCO.2022.40.17_suppl.LBA4
   Web of Science ®Google Scholar
• Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24(Suppl 1):S13–9. doi:10.1016/S0268-960X(10)70004-7
   PubMed Web of Science ®Google Scholar
• Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res. 2012;36(10):1218–1224. doi:10.1016/j.leukres.2012.05.010
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–2132. doi:10.1056/NEJMoa070594
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Thalidomide: tragic past and promising future. Mayo Clin Proc. 2004;79(7):899–903. doi:10.4065/79.7.899
   PubMed Web of Science ®Google Scholar
• Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9–19. doi:10.1182/blood-2012-02-408898
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127(21):2569–2574. doi:10.1182/blood-2016-01-693580
   PubMed Web of Science ®Google Scholar
• Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31(8):1743–1751. doi:10.1038/leu.2016.388
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337–1345. doi:10.1182/blood.2019000241
   PubMed Web of Science ®Google Scholar
• Cho SF, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020;4(17):4195–4207. doi:10.1182/bloodadvances.2020002524
   PubMed Web of Science ®Google Scholar
• Lonial S, Popat R, Hulin C, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol. 2022;9(11):e822–e32. doi:10.1016/S2352-3026(22)00290-3
   PubMed Web of Science ®Google Scholar
• Richardson PG, Trudel S, Quach H, et al. Mezigdomide (CC-92480), a potent, novel Cereblon E3 Ligase Modulator (CELMoD), combined with Dexamethasone (DEX) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial. Blood. 2022;140(Supplement 1):1366–1368.
   Google Scholar
• Lasica M, Anderson MA. Review of Venetoclax in CLL, AML and multiple Myeloma. J Pers Med. 2021;11(6):463. doi:10.3390/jpm11060463
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394. doi:10.1182/blood-2015-12-687749
   PubMed Web of Science ®Google Scholar
• Bobin A, Leleu X. Recent advances in the treatment of multiple myeloma: a brief review. Fac Rev. 2022;11:28. doi:10.12703/r/11-28
   PubMedGoogle Scholar
• Ghobrial I, Cruz CH, Garfall A, et al. Immunotherapy in multiple Myeloma: accelerating on the path to the patient. Clin Lymphoma Myeloma Leuk. 2019;19(6):332–344. doi:10.1016/j.clml.2019.02.004
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528. doi:10.1056/NEJMoa1714678
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115. doi:10.1056/NEJMoa1817249
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29–38. doi:10.1016/S0140-6736(19)31240-1
   PubMed Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841–1849. doi:10.1007/s00262-013-1493-8
   PubMed Web of Science ®Google Scholar
• Wudhikarn K, Wills B, Lesokhin AM. Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action. Best Pract Res Clin Haematol. 2020;33(1):101143. doi:10.1016/j.beha.2020.101143
   PubMed Web of Science ®Google Scholar
• Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396–410. doi:10.1016/j.ccell.2017.02.002
   PubMed Web of Science ®Google Scholar
• Tai YT, Acharya C, An G, et al. April and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225–3236. doi:10.1182/blood-2016-01-691162
   PubMed Web of Science ®Google Scholar
• Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785–795. doi:10.3324/haematol.2016.150896
   PubMed Web of Science ®Google Scholar
• Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265–1274. doi:10.1200/JCO.22.00842
   PubMed Web of Science ®Google Scholar
• Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485). doi:10.1126/scitranslmed.aau7746
   Web of Science ®Google Scholar
• Wong SW, Bar N, Paris L, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): results from a phase 1 first-in-human clinical study. Blood. 2022;140(Supplement 1):400–402. doi:10.1182/blood-2022-159009
   Google Scholar
• Bumma N, Richter JR, Dhodapkar MV, et al. LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2023;41(16_suppl):8006. doi:10.1200/JCO.2023.41.16_suppl.8006
   Web of Science ®Google Scholar
• Topp MS, Duell J, Zugmaier G, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38(8):775–783. doi:10.1200/JCO.19.02657
   PubMed Web of Science ®Google Scholar
• Cho SF, Yeh TJ, Anderson KC, Tai YT. Bispecific antibodies in multiple myeloma treatment: a journey in progress. Front Oncol. 2022;12:1032775. doi:10.3389/fonc.2022.1032775
   PubMed Web of Science ®Google Scholar
• Tan CR, Shah UA. Targeting BCMA in Multiple Myeloma. Curr Hematol Malig Rep. 2021;16(5):367–383. doi:10.1007/s11899-021-00639-z
   PubMed Web of Science ®Google Scholar
• Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4(18):4538–4549. doi:10.1182/bloodadvances.2020002393
   PubMed Web of Science ®Google Scholar
• Frerichs KA, Broekmans MEC, Marin Soto JA, et al. Preclinical activity of JNJ-7957, a novel BCMA×CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. Clin Cancer Res. 2020;26(9):2203–2215. doi:10.1158/1078-0432.CCR-19-2299
   PubMed Web of Science ®Google Scholar
• Janssen Research & Development, LLC. Janssen research & development; 2020.
   Google Scholar
• Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196–2215. doi:10.1182/bloodadvances.2020003805
   PubMed Web of Science ®Google Scholar
• Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232–1243. doi:10.1182/blood.2019003342
   PubMed Web of Science ®Google Scholar
• Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232–2244. doi:10.1056/NEJMoa2204591
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Richter J, Trudel S, et al. Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed/refractory multiple myeloma: early experience from a phase I study. Blood. 2022;140(Supplement 1):4415–4417. doi:10.1182/blood-2022-157547
   Google Scholar
• Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood. 2022;140(Supplement 1):388–390. doi:10.1182/blood-2022-166494
   PubMedGoogle Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048–2060. doi:10.1158/1078-0432.CCR-12-2422
   PubMed Web of Science ®Google Scholar
• Rendo MJ, Joseph JJ, Phan LM, DeStefano CB. CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges. Blood Lymphat Cancer. 2022;12:119–136. doi:10.2147/BLCTT.S327016
   PubMed Web of Science ®Google Scholar
• Study of bb21217 in multiple myeloma; 2021.
   Google Scholar
• bluebird bio. A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma [Internet]. clinicaltrials.gov; 2021 Mar [cited 2023 Sep 11]. Report No.: NCT03274219. Available from: https://clinicaltrials.gov/study/NCT03274219.
   Google Scholar
• Juno Therapeutics, a Subsidiary of Celgene. A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma [Internet]. clinicaltrials.gov; 2023 Feb [cited 2023 Sep 11]. Report No.: NCT04394650. Available from: https://clinicaltrials.gov/study/NCT04394650.
   Google Scholar
• clinicaltrial.gov. BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma. NCT03070327; Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03070327.
   Google Scholar
• Latorre SV. Pilot Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-BCMA (TNFRSF17) Specificity Humanized Conjugated With the Co-stimulatory Region 4-1BB and Signal-transduction CD3z (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma With Previous Treatment With Proteasome Inhibitor, Immunomodulatory Drug and Anti-CD38 Monoclonal Antibody [Internet]. clinicaltrials.gov; 2023 Aug [cited 2023 Sep 11]. Report No.: NCT04309981. Available from: https://clinicaltrials.gov/study/NCT04309981.
   Google Scholar
• clinicaltrial.gov. T cells expressing a novel fully-human anti-BCMA CAR for treating multiple myeloma. NCT03602612; 2023.
   Google Scholar
• clinicaltrial.gov. BCMA-directed CAR-T cell therapy in adult patients with multiple myeloma. NCT04318327; 2023.
   Google Scholar
• Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–1737. doi:10.1056/NEJMoa1817226
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi:10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141(3):219–230. doi:10.1182/blood.2022015526
   PubMed Web of Science ®Google Scholar
• Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA. 2023;73(3):275–285. doi:10.3322/caac.21771
   Google Scholar
• Castella M, Fernández de Larrea C, Martín-Antonio B. Immunotherapy: a novel era of promising treatments for multiple myeloma. Int J Mol Sci. 2018;19(11):3613. doi:10.3390/ijms19113613
   PubMed Web of Science ®Google Scholar
• Shimony S, Stone RM, Stahl M. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Curr Opin Hematol. 2022;29(2):63–73. doi:10.1097/MOH.0000000000000698
   PubMed Web of Science ®Google Scholar
• Slomp A, Moesbergen LM, Gong J-N, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 2019;3(24):4202–4214. doi:10.1182/bloodadvances.2019000702
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Novartis Pharmaceuticals. NCT04702425; 2023.
   Google Scholar
• ClinicalTrials.gov. A study of PRT1419 in patients with relapsed/refractory hematologic malignancies. NCT04543305; 2023.
   Google Scholar
• Caenepeel S, Brown SP, Belmontes B, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8(12):1582–1597. doi:10.1158/2159-8290.CD-18-0387
   PubMed Web of Science ®Google Scholar
• Chari A, Cornell RF, Gasparetto C, et al. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematol Oncol. 2020;38(3):353–362. doi:10.1002/hon.2723
   PubMed Web of Science ®Google Scholar
• Von Suskil M, Sultana KN, Elbezanti WO, et al. Bruton’s tyrosine kinase targeting in multiple myeloma. Int J Mol Sci. 2021;22(11):5707. doi:10.3390/ijms22115707
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Clinical research of adoptive BCMA CAR-NK cells on relapse/refractory MM. NCT03940833; 2023.
   Google Scholar
• ClinicalTrials.gov. Anti-BCMA CAR-NK cell therapy for the relapsed or refractory multiple myeloma. NCT05008536; 2023.
   Google Scholar
• Yang Y, Shi J, Gu Z, et al. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015;75(3):594–604. doi:10.1158/0008-5472.CAN-14-2362
   PubMed Web of Science ®Google Scholar
• Elbezanti WO, Al-Odat OS, Chitren R, et al. Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells. Front Pharmacol. 2022;13:894535. doi:10.3389/fphar.2022.894535
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Lin Y, Raje NS, et al. First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: updated results. J Clin Oncol. 2017;35(15_suppl):3010. doi:10.1200/JCO.2017.35.15_suppl.3010
   PubMedGoogle Scholar
• Pittari G, Vago L, Festuccia M, et al. Restoring natural killer cell immunity against multiple myeloma in the era of new drugs. Front Immunol. 2017;8:1444. doi:10.3389/fimmu.2017.01444
   PubMed Web of Science ®Google Scholar
• Vogl DT, Kaufman JL, Holstein SA, et al. Modakafusp Alfa (TAK-573), an immunocytokine, shows clinical activity in patients with relapsed/refractory multiple myeloma; updated results from a first-in-human phase 1 study. Blood. 2021;138(Supplement 1):898. doi:10.1182/blood-2021-148463
   PubMedGoogle Scholar